On June 7, the Single Distributor held a meeting with the participation of the Chimpharm JSC General Director Urbanets Izhi, Chimpharm JSC Director of HR and PR Artem Badagov and Director of Hospital Business and Interaction with government agencies Aigul Isenova, where issues such as the extension of offtake contracts, their advantages, criteria, and deployment of clusters by type of R&D centers.
To date, 8 long-term contracts for the supply of 210 names of medicines have been concluded between the Single Distributor and Chimpharm JSC. The supply of medicines according to the List of the Single Distributor has been carried out since 2014.
It should be noted that the dynamics of the Single Distributor procurement shows an annual increase in the share of purchases from Chimpharm JSC under long-term supply contracts.
Chimpharm JSC with the trademark SANTO Member of Polpharma Group is the largest pharmaceutical company in Kazakhstan and part of the international pharmaceutical group Polpharma, which operates in the markets of Central and Eastern Europe, the Caucasus and Central Asia. The history of the pharmaceutical plant of the SANTO Company has more than 135 years.
Among Kazakhstan pharmaceutical companies Chimpharm JSC is the market leader in value terms.
One of the key issues of the meeting was the extension of existing offtake contracts, which are effective tools for supporting and developing the Kazakh pharmaceutical industry.
Kazakhstan pays great attention to the development of the domestic pharmaceutical industry. The Head of State set the task of bringing the share of domestic production to 50% in the pharmaceutical market by 2025.
Naturally long–term contracts are a good incentive for the development of local producers, which will ensure, among other things, the achievement of the goal outlined by the President.
The result of the discussion of the topic relevant to all DGP was a common understanding of the need to develop criteria for determining the duration of delivery dates and conducting an appropriate analysis of the domestic pharmaceutical market to develop appropriate proposals.
To provide the population with affordable and high-quality drugs, Single Distributor has developed an initiative to create and restart pharmaceutical clusters. The task of pharmaceutical clusters is to contribute to solving the problems of the pharmaceutical industry development.
It should be recalled that earlier, on April 14 of this year, as part of a working trip to Shymkent, the Single Distributor held a meeting with the Akimat of Shymkent on the creation of pharmaceutical clusters in the region by the type of R&D centers.
The meeting participants were presented with state support tools for the development of pharmaceutical clusters. The parties noted that government agencies, science and business should work together on the tasks set and develop in tandem.
Based on the results of the round table, the Single Distributor developed proposals for the development of the production of expensive innovative products, the promotion of the industry in the direction of technology transfer, its digitalization.
Also, within the framework of this working trip, to inspect the production site, get acquainted with the range of medicines and medical equipment produced, and discuss the possibility of localization, representatives of the Single Distributor visited the production site of Chimpharm JSC.
In the South Kazakhstan Medical Academy, in which, in addition to medical specialties, there is a faculty of pharmacy, research is being conducted in clinical medicine, research in theoretical and experimental medicine.
Since the company has an R&D center as part of Santo, which developed 23 new products, modernized 3 products, validated 5 new methods in 2021, it is proposed to place the research and production center (R&D) on the basis of Chimpharm JSC. The presence of its own R&D at this production site became the basis for combining the functions: research and production as part of a cluster.
The clinical base of the research and production center (R&D) is the location of which is offered on the basis of two large city hospitals: Shymkent City Multidisciplinary Hospital No. 2 and City Cardiology Center with a total bed capacity of more than 500 beds.
Thus, the development of the cluster initiative in Kazakhstan is one of the powerful tools for implementing the Effective Medicine Model. Purpose of this model is to increase the effectiveness of treatment and improve the health of citizens of Kazakhstan to ensure sustainable socio-demographic development of the country.
Following the meeting, the parties expressed interest in cooperation. It was noted that it is necessary to consolidate joint efforts in order to achieve more effective indicators of the development of the industry.
Also, the parties noted that increasing the volume of production of original domestic drugs requires close integration of science, production and education in the field of pharmaceutical production technology.
Reference:
Chimpharm JSC (trademark SANTO Member of Polpharma Group) is part of the international pharmaceutical Group Polpharma, operating in the markets of Central and Eastern Europe, the Caucasus and Central Asia. The company develops, manufactures and supplies affordable high quality medicines to the markets of Kazakhstan and Central Asia.
SANTO is the leader of the pharmaceutical market in Kazakhstan with a portfolio of more than 240 generic drugs in 12 pharmacotherapeutic groups for the treatment of diseases in various areas of therapy.
Currently, the Company is implementing the largest investment project to modernize existing pharmaceutical production facilities in accordance with international GMP standards, the volume of which is about 108 million US dollars.
The SANTO plant was founded in 1882 by merchants Ivanov and Savenkov and produced the Santonin preparation based on wormwood, the sprig of which is depicted on the coat of arms of the city of Shymkent.
.png)
.jpeg)